Holen Sie sich die Stockscreener-App
22.23
1.46%
-0.33
Handel nachbörslich:
22.47
0.24
+1.08%
Schlusskurs vom Vortag:
$22.56
Offen:
$22.48
24-Stunden-Volumen:
683.01K
Relative Volume:
0.95
Marktkapitalisierung:
$653.12M
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-3.6563
EPS:
-6.08
Netto-Cashflow:
$-121.61M
1W Leistung:
+8.76%
1M Leistung:
+4.96%
6M Leistung:
-10.94%
1J Leistung:
-6.00%
1-Tages-Spanne:
$21.50
$22.59
1-Wochen-Bereich:
$19.93
$22.84
52-Wochen-Spanne:
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Vergleichen Sie ANAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
22.23 | 600.54M | 17.16M | -163.62M | -121.61M | -6.08 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
Trading (ANAB) With Integrated Risk Controls - news.stocktradersdaily.com
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by BNP Paribas Financial Markets - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Up 6.6%Here's Why - MarketBeat
AnaptysBio's (ANAB) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Woodline Partners LP Purchases 25,094 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Two Sigma Advisers LP Has $3.88 Million Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Voloridge Investment Management LLC Sells 85,708 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Given Outperform Rating at Wedbush - Defense World
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Analyst Upgrade - MarketBeat
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at Guggenheim - MarketBeat
AnaptysBio (NASDAQ:ANAB) Earns Buy Rating from Guggenheim - Defense World
Northern Trust Corp Grows Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Two Sigma Investments LP Has $4.66 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $90.00 at Guggenheim - Defense World
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock - Benzinga
AnaptysBio (ANAB) Maintains Buy Rating with Raised Price Target | ANAB Stock News - GuruFocus
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday - Benzinga
Guggenheim raises AnaptysBio stock target to $90, maintains Buy By Investing.com - Investing.com India
Guggenheim raises AnaptysBio stock target to $90, maintains Buy - Investing.com
AnaptysBio, Inc. (NASDAQ:ANAB) Position Lessened by BNP Paribas Financial Markets - Defense World
AnaptysBio (ANAB) Sees Price Target Uplift Amid Positive Developments | ANAB Stock News - GuruFocus
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilim - GuruFocus
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 | ANAB Stock News - GuruFocus
AnaptysBio to Host Investor Call for Phase 2b RENOIR Trial Data on Rosnilimab for Rheumatoid Arthritis - Nasdaq
Anaptys to Announce Updated Data from Phase 2b Trial of - GlobeNewswire
New PD-1 Drug Trial Data: Rosnilimab Shows Promise for Rheumatoid Arthritis TreatmentKey Results Coming - Stock Titan
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Rafferty Asset Management LLC - MarketBeat
Frazier Life Sciences Management L.P. Sells 635,470 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by D. E. Shaw & Co. Inc. - MarketBeat
Soleus Capital Management L.P. Takes Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Graham Capital Management L.P. Buys New Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Northern Trust Corp Boosts Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Dimensional Fund Advisors LP Decreases Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Sanofi Acquires New Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Jacobs Levy Equity Management Inc. Boosts Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Wolfe Research maintains Outperform on AnaptysBio shares, $25 target By Investing.com - Investing.com UK
Ensign Peak Advisors Inc Has $2.85 Million Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Dimensional Fund Advisors LP Decreases Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
The Manufacturers Life Insurance Company Sells 5,594 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Granahan Investment Management LLC Takes Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Reports Strong Q1 2025 Results and Progress - TipRanks
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Tower Research Capital LLC TRC - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Wells Fargo & Company MN - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Bridgefront Capital LLC Acquires New Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Fairmount Funds Management LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Q2 EPS Estimates for AnaptysBio Raised by Leerink Partnrs - MarketBeat
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):